Breadcrumb

Cancer Enterprise Global Pipeline

Daiichi Sankyo Cancer Enterprise Global Pipeline

As of January 2017

These are investigational agents and are not approved by the FDA or any other worldwide regulatory agency as a treatment for any indication. Efficacy and safety have not been established. There is no guarantee that these investigational agents will become commercially available.

ADC Franchise

 

Compound Tumor Type Relevant
Pathway
Highest Phase of Development Location
DS-8201

Breast Cancer

Gastric Cancer

HER2

Phase 1

US / Japan

U3-1402

Breast Cancer

HER3

Phase 1

Japan

 

AML Franchise

 

Compound Tumor Type Relevant
Pathway
Highest Phase of Development Location

Quizartinib (AC220)

Newly-Diagnosed Acute Myeloid Leukemia

FLT3

Phase 3

US / EU/ Asia

Quizartinib (AC220)

Relapsed/Refractory Acute Myeloid Leukemia

FLT3

Phase 3

US / EU/ Asia

Quizartinib (AC220)

Relapsed/Refractory Acute Myeloid Leukemia

FLT3

Phase 1

Japan

DS-3032

Leukemia

MDM2

Phase 1

US

DS-3201

Acute Myeloid Leukemia

EZH1/2

Phase 1

Japan

PLX51107

Hematological Malignancies

BRD4

Phase 1

US

 

Late-Stage Programs

 

Compound Tumor Type Relevant
Pathway
Highest Phase of Development Location

Pexidartinib (PLX3397)

Tenosynovial Giant Cell Tumor (TGCT)*

CSF-1R

Phase 3

US / EU

Pexidartinib (PLX3397)

Glioblastoma

CSF-1R

C-KIT

Phase 2

US

Pexidartinib (PLX3397) [in combination with pembrolizumab]

Melanoma, Solid Tumor

CSF-1R

Phase 1/2

US

Pexidartinib (PLX3397)

Melanoma

C-KIT

Phase 1/2

Asia

Patritumab (U3-1287)

Head & Neck Cancer

HER3

Phase 2

EU

DS-1647

Glioblastoma

Oncolytic HSV-1

Phase 2

Japan

*Tenosynovial giant cell tumor (TGCT) is also known as pigmented villonodular synovitis (PVNS) or giant cell tumor of the tendon sheath (GCT-TS).

 

Early-Stage Programs

 

Compound Tumor Type Relevant
Pathway
Highest Phase of Development Location

Pexidartinib (PLX3397)

Solid Tumor

CSF-1R

Phase 1

Asia

PLX73086 (AC708)

Tenosynovial Giant Cell Tumor (TGCT)*

CSF-1R

Phase 1

US

PLX7486

Solid Tumor

FMS/TRK

Phase 1

US

PLX8394

Solid Tumor

BRAF

Phase 1

US

PLX9486

Solid Tumor

KIT

Phase 1

US

DS-3032

Solid Tumor, Lymphoma

MDM2

Phase 1

US / Japan

PLX8394

Solid Tumor

BRAF

Phase 1

US

DS-3201

Non-Hodgkin’s Lymphoma

EZH1/2

Phase 1

Japan

DS-8895

Solid Tumor

EPHA2

Phase 1

Japan

DS-8273

Solid Tumor

DR5

Phase 1

US

DS-6051

Solid Tumor

NTRK/ROS1

Phase 1

US / Japan

DS-5573

Solid Tumor

B7-H3

Phase 1

Japan

DS-1123

Solid Tumor

FGFR2

Phase 1

Japan

U3-1784

Solid Tumor, Lymphoma

FGFR4

Phase 1

EU

*Tenosynovial giant cell tumor (TGCT) is also known as pigmented villonodular synovitis (PVNS) or giant cell tumor of the tendon sheath (GCT-TS).

daiichi-sankyo-oncology-pipeline-in-the-united-states-QuickLink

More Stories

Phase 3 Oncology Compounds

Daiichi Sankyo currently has three compounds in phase 3 clinical development with unique mechanisms of action...

read more ...